RIGL Financial Facts
Interest income: 110KContract revenues from collaborations: 3.76M
See Full Income Statement
Cash and cash equivalents: 25.95M
Other long-term liabilities: 8K
See Full Balance Sheet
Rigel Pharmaceuticals, Inc. (RIGL) Earnings
|
Expand Research on RIGL
| Next EPS Date | 4/30/24 | EPS Growth Rate | +62.5% |
|---|---|---|---|
| Average EPS % Beat Rate | +81.8% | Revenue Growth Rate | +21.1% |
| Average % Move 1-Wk after EPS | -3.0% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 3/1/22 |  |
Q421 | -$0.13 | -$0.13 | $0.00 | $20.4M | $21.9M | N/A |  | | Details |
| 3/7/23 | Q422 | $0.01 | -$0.09 | +$0.10 | $51.3M | $36.52M | N/A | | | Details | |
| 3/6/18 | |
Q417 | -$0.18 | -$0.13 | -$0.05 | N/A | $40K | = | | | Details |
8/2/16  |
|
Q216 | -$0.15 | -$0.20 | +$0.05 | $8.6M | $4.01M | N/A | | | Details |
| 8/8/18 | |
Q218 | -$0.16 | -$0.16 | $0.00 | $1.8M | $180K | N/A | | | Details |
| 8/2/22 | Q222 | -$0.08 | -$0.12 | +$0.04 | $29.8M | $23.82M | N/A | | | Details | |
| 11/6/18 | |
Q318 | -$0.14 | -$0.15 | +$0.01 | $4.9M | $3.93M | N/A | | | Details |
| 5/3/22 | |
Q122 | -$0.16 | -$0.14 | -$0.02 | $16.74M | $17.54M | N/A | | | Details |
